A review of preclinical and clinical evidence suggests GLP-1 receptor agonists may do more than lower A1c and weight: they also appear to reduce chronic inflammation linked to heart disease and other common conditions. The review found anti-inflammatory effects across multiple organ systems, supporting the idea that GLP-1RAs may provide dual cardiometabolic and immunomodulatory benefit.

Why It Matters To Your Practice

• Chronic inflammation contributes to diabetes, cardiovascular disease, neurodegenerative disorders, and inflammatory bowel disease.

• For NPs and PAs managing patients with type 2 diabetes or obesity, GLP-1RAs may offer added value beyond glycemic control and weight reduction.

• This emerging mechanism may help explain some of the cardiovascular benefits already seen with the class.

Clinical Benefits

• Established benefits include lower glucose, weight loss, and improved cardiovascular outcomes.

• Evidence summarized in the review suggests GLP-1RAs may directly modulate inflammatory pathways across organ systems.

• If confirmed, that dual metabolic and anti-inflammatory effect could broaden how clinicians think about treatment selection in high-risk cardiometabolic patients.

Managing Risks

• This was a review, not a new randomized trial, so it cannot prove causality between GLP-1RA use and reduced inflammation.

• Key unanswered questions include the exact molecular mechanisms, which patients benefit most, and whether these effects extend to non-metabolic inflammatory diseases.

• Continue to counsel patients on known adverse effects, contraindications, and monitoring needs when prescribing GLP-1RAs.

The Bottom Line

• GLP-1RAs remain established therapies for type 2 diabetes and obesity, with proven cardiometabolic benefits.

• Emerging evidence suggests they may also curb inflammation tied to heart disease, but more research is needed before using them primarily for anti-inflammatory indications.

• For now, this review reinforces the class's potential added value in patients with overlapping metabolic and cardiovascular risk.